Prescribed drugs firm Divis Laboratories on Friday reported a 26% rise in its consolidated web revenue at ₹702 crore as in comparison with ₹557 crore in the identical quarter final yr. In the meantime, its income from operations rose about 15% to ₹2,254 crore from ₹1,960.6 crore year-on-year (YoY).
Revenue earlier than tax (PBT) got here in at ₹851 crore, up 4.5% over ₹814 crore within the year-ago quarter. Divi’s Labs foreign exchange acquire in Q1 FY23 rose to ₹56 crore as in opposition to the acquire of ₹20 crore in Q1 FY22. It witnessed an increase in tax expense at ₹149 crore from ₹257 crore (YoY).
Shares of Divis Labs have been buying and selling about 3% decrease on the BSE at ₹3,820 apiece on the BSE in Friday’s afternoon offers. The pharma inventory is down about 18% in 2022 (YTD) to this point.
Divi’s Laboratories Ltd is an of Energetic Pharmaceutical Components (APIs) and Intermediates manufacture and is engaged in manufacture of main generic compounds Nutraceutical substances and customized synthesis of APIs and intermediates for international innovator firms.
Obtain The Mint Information App to get Every day Market Updates & Stay Enterprise Information.
Extra
Much less
Supply: Live Mint